Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.54 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | YWHAG | P61981 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.51 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | IAPP | P10997 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781984 | 0.87 | APP (0.59) | APPTDP1MAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL490480 | 0.87 | APP (1.00) | APPTDP1IGF1RALOX15ERCC1 | |
| SCHEMBL23086060 | 0.86 | APP (0.58) | APPTDP1MAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL28209720 | 0.84 | ALDH1A1 (0.69) | APPTDP1IGF1RALOX15ERCC1 | |
| SCHEMBL56986 | 0.84 | TDP1 (0.59) | APPTDP1MAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL20914966 | 0.84 | APP (0.84) | APPTDP1IGF1RALOX15ERCC1 | |
| SCHEMBL3735867 | 0.84 | APP (0.62) | APPTDP1IGF1RALOX15ERCC1 | |
| SCHEMBL305392 | 0.84 | TDP1 (0.68) | APPTDP1MAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL9857796 | 0.84 | APP (0.55) | APPTDP1ALOX15MAPK1L3MBTL1 | |
| SCHEMBL28039284 | 0.84 | APP (0.59) | APPTDP1MAPK1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094973-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-04-19 | — | — | US | disclosed |
| US-8088818-B2 | Catechol-based derivatives for treating or preventing diabetics | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-01-03 | — | — | US | disclosed |
| US-20110224260-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | NATIONAL TAIWAN UNIVERSITY (TW) | 2011-09-15 | — | — | US | disclosed |
| US-20090143397-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | LOTUS PHARMACEUTICAL CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094973-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | SLC5A2, SLC5A1, SLC2A8 | APP 3380/4885TDP1 3767/4885IGF1R 1552/4885 |
| US-20110224260-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | SLC5A2, SLC5A1, SLC2A8 | APP 3380/4885TDP1 3767/4885IGF1R 1552/4885 |
| US-20090143397-A1 | CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS | SLC5A2, SLC5A1, SLC2A3 | APP 3044/4885TDP1 3586/4885IGF1R 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.